- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 193 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- July 2024
- 136 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- August 2024
- 140 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- May 2024
- 139 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 134 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- March 2024
- 150 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- May 2024
- 170 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- August 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Report
- July 2024
- 231 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Drug Pipelines
- June 2024
- 80 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Clinical Trials
- April 2024
- 240 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Drug Pipelines
- April 2024
- 202 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- May 2024
- 160 Pages
Global
From €4723EUR$4,949USD£3,957GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more